IT-ACTS

Our Cell-Therapy Platform

A highly adaptable, versatile, and effective living drug platform for a wide range of indications.

At the heart of our innovation is the Immune Triad Therapy with Armed CAR T-cell Supercharger (IT-ACTS), a proprietary cell-based platform engineered to function as a swiss-army knife against cancer.

Mechanism & Core Advantages

The "Living Drug" Mechanism

IT-ACTS operates as a "miniature factory" within the body, precisely delivering therapeutic agents directly to diseased tissues. This unique mechanism is engineered to sustain a durable, long-term immune response, setting it apart.

Adaptability & Customization

While initially focused on challenging cancers, this adaptable IT-ACTS platform is being developed for a wide range of indications. Its hallmark customizability allows it to be loaded with diverse immune modulators and signaling molecules to precisely meet different clinical needs.

Deployment & Therapeutic Scope

Autologous & Allogeneic Deployment

Our platform offers dual capability for both autologous (personalized) and allogeneic ("off-the-shelf") deployment, ensuring tailored approaches and broad accessibility. This versatility allows IT-ACTS to meet diverse clinical and operational needs, driving faster innovation.

Broad Clinical Applications

The adaptable design of IT-ACTS lends itself to a wide range of clinical scenarios, delivering optimal outcomes across various diseases. It seamlessly integrates with combination therapies, amplifying therapeutic responses and filling gaps in existing treatments.

Patient-Centric Design & Broad Impact

Uncompromising Patient Safety

Built with patient safety as a guiding principle, IT-ACTS minimizes off-target effects and avoids many toxicities common with traditional systemic therapies. Its self-contained, 'living-drug' design allows for potent, localized treatment with little to no side effects, thereby preserving quality of life.

Adaptable Clinical Applications

The broad clinical potential of IT-ACTS extends across an array of diseases, from solid tumors to hard-to-treat conditions like fibrosis. By overcoming key resistance mechanisms and synergizing with combination therapies, IT-ACTS boosts effectiveness without compromising safety.